Fig. 3.

(A) Plasma concentrations of sunitinib at 1 hour post oral dose (20 mg/kg) in wild-type (WT) mice after administration of a selective P-gp inhibitor [LY335979 (25 mg/kg)], selective Bcrp inhibitor [Ko143 (10 mg/kg)], both LY335979 and Ko143, and a dual P-gp/Bcrp inhibitor [elacridar (10 mg/kg)], selective P-gp inhibitor in Bcrp1(−/−) and selective Bcrp inhibitor in Mdr1a/b(−/−) mice. The plasma concentrations with pharmacological inhibition are compared at 1 hour in transgenic transporter-deficient mice. (B) Corresponding brain concentrations in the treatment group. (C) Brain-to-plasma ratios in corresponding treatment groups.